Keyword: Juluca (dolutegravir and rilpivirine)
Gilead Sciences launched its first national TV campaign for HIV treatment Biktarvy featuring a broad range of different people living with HIV.
In the Gemini studies, Dovato showed it could match up to a three-drug regimens, but GlaxoSmithKline has some more convincing to do.
CEO Emma Walmsley just put cancer back on the front burner, but with its $5 billion Tesaro buy and in-house candidates, the pipeline is pumping, she says.
Merck scored FDA nods for a new HIV drug called doravine, both alone and in a combo with other therapies.
A cabotegravir/rilpivirine combo as a monthly HIV treatment showed similar efficacy to a standard three-drug therapy.
Activists are pushing the federal government to break Gilead's Truvada patent due to access concerns.
ViiV's dolutegravir and lamivudine combo works as well as standard three-drug HIV treatment, as Juluca maintains viral suppression through 100 weeks.
Analysts hold back some optimism as they wait for the new therapy's resistance profile that has been a key question around HIV two-drug approach.
GSK execs lauded their HIV drugs Triumeq and Tivicay this week, but both fell short of forecasts—thanks to Gilead's new Biktarvy, analysts say.